Organization Overview
Timeline
Active Ingredients
Indications
Clinical Trials
Targets and Mechanisms
bevacizumab (avastin) (1 trial)
ranibizumab (lucentis) (1 trial)
Macular Degeneration (Phase 3)
Trials (1 total)
Trial APIs (2 total)